{"id":991852,"date":"2026-08-06T23:27:59","date_gmt":"2026-08-07T03:27:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-reports-second-quarter-2026-financial-results\/"},"modified":"2026-08-06T23:27:59","modified_gmt":"2026-08-07T03:27:59","slug":"profound-medical-reports-second-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/profound-medical-reports-second-quarter-2026-financial-results\/","title":{"rendered":"Profound Medical Reports Second Quarter 2026 Financial Results"},"content":{"rendered":"
\n

\n \u2013 Operating expenses decline 16%, helping drive a 39% improvement in net loss \u2013<\/em>\n <\/p>\n

\n \u2013 Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing \u2013<\/em>\n <\/p>\n

\n \u2013 Strong clinical, commercial and reimbursement momentum continues \u2013<\/em>\n <\/p>\n

\n \u2013 Company reiterates full-year 2026 revenue guidance \u2013<\/em>\n <\/p>\n

\n \u2013 Announces first employer owned health plans to list the TULSA Procedure\u2122 as a covered service \u2013<\/em>\n <\/p>\n

TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp.<\/a> (NASDAQ:PROF; TSX:PRN) (\u201cProfound\u201d or the \u201cCompany\u201d), a commercial-stage medical device company that develops and markets innovative interventional MRI (\u201ciMRI\u201d) procedures, today announced financial results for the second quarter ended June 30, 2026. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).\u00a0<\/p>\n

\u201cCommercial momentum continued to accelerate during the second quarter,” said Arun Menawat, Profound’s CEO and Chairman. \u201cWe received over $7.0 million in new purchase orders, a new quarterly record. Approximately $2.5 million of those orders were recognized as revenue during the quarter, while approximately $3.1 million was shipped in July and will be recognized in the third quarter. The shipment timing reflected a temporary logistics issue\u2014not customer demand\u2014and, absent the timing difference, second quarter revenue would have increased approximately 153% year-over-year. The logistics issue has since been resolved.<\/p>\n

Beyond top-line growth, our business model continued to demonstrate meaningful operating leverage. Gross margin remained above our long-term target of 70%, operating expenses declined 16%, and net loss improved by 39% year-over-year.<\/p>\n

Momentum has continued into the third quarter, including another monthly record for new order activity in July and exceptional physician engagement at SRS2026 that generated more than 160 qualified commercial opportunities over just four days. Based on continued payer coverage expansion, growing clinical validation, and a strengthening sales pipeline, we believe we are now in the strongest commercial position in the Company’s history. Based on this momentum and our improved visibility into the second half of the year, we are reiterating the $25.0 million bar we previously set for 2026 total revenue.”<\/p>\n

\n Business Highlights<\/strong>\n <\/p>\n

\n Clinical Momentum<\/u>\n <\/p>\n